US$ 27.66
retatrutide prescription Phase 3: 60% Achieved Surgical-Level Weight Loss Retatrutide, an experimental weight-loss drug,
Description
And when protein drops, muscle follows
font: 400 14px/1.35 Poppins,Helvetica Neue,Verdana,Arial,sans-serif

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
Doctor-led GLP-1 medical weight loss program for teens and young adults (ages 12+)

The FDA has approved GLP-1 drugs for weight loss among kids 12 and older
